Company news
Estrella Immunopharma, Inc. news in 2025
Estrella Immunopharma, Inc.'s news releases, calls and decks from 2025, newest first.
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
December 4, 2025
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
November 3, 2025
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
October 6, 2025
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
June 5, 2025
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
June 3, 2025
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas
May 29, 2025
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
February 21, 2025